B A S E C A R E
“The Spike in Demand for Assisted Reproductive Technology” Listed in Hot Spot of Sina Weibo, and Basecare Medical Strives to Meet the Market of CNY300 Billion
September 15, 2021 · Suzhou
Today, the news investigation of “the spike in demand for assisted reproductive technology” reported by CCTV Financial draws much attention that multiple parties participated in a lively discussion on this topic

Today, the news investigation of “the spike in demand for assisted reproductive technology” reported by CCTV Financial draws much attention that multiple parties participated in a lively discussion on this topic.


With the penetration of the “three child policy” in China, hospitals have welcomed more and more patients for assisted reproduction counseling. Showed by statistics, the current infertility rate of childbearing couples in China has climbed to 12%-18%. Owing to the increasing pregnant age, cases of DNA aneuploid have upsurged by 50%-60% in the last 40 years. It is generally acknowledged that euploidy abortion can be prevented by dealing with maternal rejection reasons, such as immunity, endocrinology and coagulation, while aneuploidy miscarriage is impossible to be avoided. At present, the most mainstream way of in vitro fertilization among various assisted reproductive technology is what we call “test-tube babies”, whose birth roughly reached 300 thousand a year, said by experts.
Affected by the frequent incidence of infertility, lifestyle changes and domestic policy of birth, assisted reproductive industry presents an acceleration of developmental momentum. Currently, the market scale of more than CNY300 billion for assisted reproduction is freed up. As the “three-child policy” and relevant supporting policies are introduced successively, the entire market will expand further with the popularization of assisted reproduction in China, showing the massive development space and potential.
According to the Report on Research and Investment Prospects of Human Assisted Reproduction Industry in China (2016-2022) issued by Intelligence Research Group, PGT will become the most widely used assisted reproductive technology. The present market space of PGD/PGS in China is about CNY2.54 billion, in which PGT occupies nearly 0.8 billion with a high growth rate in the future. Every year sees 900 thousand children born with birth defects with a rate of 5.6% in China. As emphasized in the Prevention, Treatment, and Development of Social Security System of Rare Diseases in China, the primary prevention screening shall be vigorously promoted with PGT being one of important means of birth defect prevention which can be done in preconception diagnosis instead of prenatal diagnosis for the eugenic purpose with higher fertility rate and lower birth defect rate. There will be brilliant prospects for PGT development with the advancement of assisted reproduction industry.
Taking the lead in the assisted reproduction field of NGS segment market, Basecare Medical has initiated PGT development and its market in China as the only innovative medical device company in China that has obtained NMPA approval for assisted reproductive gene testing with long- term dominant in China’s PGT market. Basecare Medical acts as an innovative platform of integrated solution to assisted reproduction, with PGT service as the main product applied to genetic disease testing prior to the embryo transfer to reduce the IVF probability of failure. Data demonstrate that the success rate of pregnancy achieved by Basecare can reach 72% with sharply lowered miscarriage rate as 6.9%. With the optimization of fertility policy, the penetration rate of assisted reproductive gene testing industry will continue to develop, which also provides more opportunities for Basecare Medical.
The assisted reproduction market is expected to maintain a high growth trend with the increasing demand. We will sustain the expansion of production line and boost the layout of industrial chain to satisfy the enormous market demand. You can look forward to our future growth.